Sorafenib is an anticancer drug is used to treat late stage kidney and liver cancer. Sorafenib is used to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). Sorafenib is also used to treat hepatocellular carcinoma (a type of liver cancer) that cannot be treated with surgery and a certain type of thyroid cancer that has spread to other parts of the body and cannot be treated with radioactive iodine. Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. There are many reported analytical methods for estimation of Sorafenib. The present work list outs the vario...
Objective: The aim of the research work is to develop and validate a novel, sensitive, specific, rap...
Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocel...
The bi-aryl urea multi-kinase inhibitor Sorafenib (BAY 43-9006, Nexavar) was initially approved for ...
Sorafenib is an anticancer drug is used to treat late stage kidney and liver cancer. Sorafenib is us...
Sorafenib is a multikinase inhibitor and an oral anticancer drug approved for the treatment of patie...
Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of pat...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Prel...
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Prel...
Sorafenib is a relatively new antitumour drug, approved in 2005. It exerts its antiproliferative ac...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocel...
Objective: The aim of the research work is to develop and validate a novel, sensitive, specific, rap...
Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocel...
The bi-aryl urea multi-kinase inhibitor Sorafenib (BAY 43-9006, Nexavar) was initially approved for ...
Sorafenib is an anticancer drug is used to treat late stage kidney and liver cancer. Sorafenib is us...
Sorafenib is a multikinase inhibitor and an oral anticancer drug approved for the treatment of patie...
Pharmacokinetics and dose-finding studies on sorafenib were conducted on heterogeneous groups of pat...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Traditional medicines have become the most productive source of leads for drugs development, particu...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Prel...
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Prel...
Sorafenib is a relatively new antitumour drug, approved in 2005. It exerts its antiproliferative ac...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocel...
Objective: The aim of the research work is to develop and validate a novel, sensitive, specific, rap...
Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocel...
The bi-aryl urea multi-kinase inhibitor Sorafenib (BAY 43-9006, Nexavar) was initially approved for ...